Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | STAT6 | P42226 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MT-CO2 | P00403 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3593084 | 1.00 | ALDH1A1 (0.55) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL5752117 | 0.87 | ALDH1A1 (0.50) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL28431888 | 0.86 | ALDH1A1 (0.55) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL18009424 | 0.85 | ALDH1A1 (0.53) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL18009426 | 0.85 | ALDH1A1 (0.53) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL18009314 | 0.85 | ALDH1A1 (0.53) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL2273021 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL5750904 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL5750900 | 0.84 | ALDH1A1 (0.47) | ALDH1A1GAAHPGDCYP1A2CYP3A4 | |
| SCHEMBL22593164 | 0.82 | ALDH1A1 (0.56) | ALDH1A1GAAHPGDCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2964223-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2964222-B1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9493440-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9493440-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-11-15 | — | — | US | disclosed |
| US-9416126-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-9416126-B2 | Compounds inhibiting leucine-rich repeat kinase enzyme activity | MERCK SHARP & DOHME CORP. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20160009696-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| US-20160009689-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009689-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2016-01-14 | — | — | US | disclosed |
| US-20160009696-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2014134772-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | MERCK SHARP & DOHME CORP. (US) | 2014-09-12 | — | — | WO | disclosed |
| US-5116842-A | Analgesics | GLAXO GROUP LIMITED (GB) | 1992-05-26 | — | — | US | disclosed |
| US-5109008-A | Analgesics, diuretics, antiischemic agents | GLAXO GROUP LIMITED (GB) | 1992-04-28 | — | — | US | disclosed |
| EP-0398720-A2 | Piperazine derivatives | GLAXO GROUP LIMITED (GB) | 1990-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009696-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | ALDH1A1 4279/4885GAA 396/4885HPGD 2956/4885 |
| US-20160009689-A1 | COMPOUNDS INHIBITING LEUCINE-RICH REPEAT KINASE ENZYME ACTIVITY | LRRK2, LRRC47, LIMK2 | ALDH1A1 4279/4885GAA 396/4885HPGD 2956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.